The performance of China’s biomedical innovation: a scientometric analysis by unknown
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2016. This article is published with open access at link.springer.com life.scichina.com   link.springer.com 
                  
email: tang.xiaoli@imicams.ac.cn 
• INSIGHT • October 2016  Vol.59  No.10: 1074–1082 
 doi: 10.1007/s11427-016-5078-6 
The performance of China’s biomedical innovation: 
a scientometric analysis 
Xiaoli Tang & Jian Du 
Institute of Medical Information & Library, Chinese Academy of Medical Sciences, Beijing 100005 
Received May 26, 2016; accepted June 7, 2016; published online July 19, 2016 
 





Recognizing the importance of innovation in science and 
technology (S&T) as a driver of continued economic 
growth, China has introduced new policies to facilitate and 
encourage innovation and made significant progress in S&T 
innovation in the past decade. The total volume of innova-
tion resources is steadily growing. Commensurate with its 
status as the second largest economy in the world, China 
ranks second globally now in research and development 
(R&D) investment. The R&D intensity, i.e. R&D expendi-
ture as a percentage of gross domestic product (GDP), 
which now stands at 2.1%, is already close to that of an in-
novative country (3%4%). Meanwhile, China ranks first 
for science and technology workforce in the world in 2014. 
Resulting from the economic investment and adequacy of 
S&T workforce, China has also made great strides in scien-
tific output. Since 2010, China’s total number of scientific 
publications has ranked second in the world for six consec-
utive years, second only to the US. Moreover, China’s sta-
tus as the second largest country contributor to the Nature 
Index, demonstrated its strength in high-quality primary 
research. The number of domestic resident invention patent 
applications rose to 1 million in 2015, indicating that China 
continues to top patent application list globally for the fifth 
consecutive year.  
With regard to the citation impact of scientific publica-
tions, China now ranks fourth in terms of both total citations 
and the top 1% most cited papers as a whole 
(http://www.nsfc.gov.cn/publish/portal0/tab38/info51767.ht
m). However, the average academic impact of Chinese re-
search does not match its exceptional growth in scientific 
investment and output. While China is making great pro-
gress in high-quality publications, it lags behind the world 
average in many subject areas in terms of Normalized Cita-
tion Impact, which takes into account the differences in ci-
tations for research fields and time periods and compares 
the performance of an institution/country to the average 
performance of the world. Comparing the impact of Chinese 
academic performance in selected subject areas reveals that 
China does not have a strength in biological and medical 
sciences as it does in chemistry and physical sciences. The 
distribution of publication output by discipline provides an 
indication of the priority and emphasis of scientific research 
in different subject areas. According to Science and Engi-
neering Indicator 2016 (http://www.nsf.gov/statistics/2016/ 
nsb20161/#/downloads/report), the publication portfolios of 
the five major producers—US, EU, China, Japan, and In-
dia—have distinct differences by academic area. Almost 
half (48.7%) of the US’ publications are focused on biolog-
ical sciences, medical sciences, and other life sciences, 
compared to 38.2% for the world at large. But this percent-
age is only 20.9% for China, smaller than EU (40.8%), Ja-
pan (39.6%) and even India (36.2%). China has the highest 
concentration of publications in engineering (37.7%), bio-
logical sciences (12.1%) and chemistry (10.6%), with the 
medical sciences only accounting for 8.7%, much lower 
than the world’s level (21.2%). So, while Youyou Tu was 
awarded China’s first Nobel Prize in medical science in 
2015 for the work that led to a treatment for malaria that has 
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saved countless lives, China lags behind in producing 
breakthrough research in biomedical sciences with a 
wide-ranging impact.   
There are some research focused on the relationships 
between R&D input and scientific output. Nevertheless little 
of such research, especially empirical research, has been 
carried out at the country level. When countries in the world 
are gearing up efforts to increase R&D investment, it is im-
perative for policy makers to understand the relationship 
between R&D input and scientific output and find efficient 
ways to better fund scientific research. To this end, using 
bibliographic data, this paper examines China’s biomedical 
innovation achievements over the past decade from the 
perspective of R&D input (the funding for biomedical sci-
ences and S&T workforce) and scientific output ((publica-
tions, especially high-quality publications) and patents (es-
pecially high-valued patents) in biomedical sciences). We 
place China in an international context to understand the 
key driving forces which affect innovation and suggest 
remedies to promote China’s biomedical innovation.  
The publication and citation data was retrieved from 
Thomson Reuters Web of Science and Incites. The 
high-quality publications were limited only to top life sci-
ences journals and top clinical research journals. The 33 top 
life sciences journals, including Science, Nature, Cell, etc., 
are identified through Nature Index (http://www.      
natureindex.com/faq#methodology6). The top 5 and top 18 
clinical research journals, including The New England 
Journal of Medicine, The Lancet, JAMA, Annals of Internal 
Medicine, and Nature Medicine, etc., are proposed in 2015 
by a Lancet article, in which the authors compared the pub-
lic input and output for biomedical research in the European 
Union and the United States (Bouillon et al., 2015). The 
high-value patents are referred to triadic patent families, and 
key patents of US Food and Drug Administration (FDA) 
approved drugs, which are analyzed based on the primary 
data from OECD Statistic, FDA annual Orange Book and 
United States Patent and Trademark Office (USPTO).   
BIOMEDICAL RESEARCH FUNDING AND 
WORKFORCE 
China’s biomedical research took off in recent ten years. 
From 2004 to 2011, medical research funding increased 
from 1.6 billion to 4.9 billion dollars, at an annual rate of 
16.9%, with the highest annual growth rate in selected 
countries/regions, including Australia (9.3%), Japan (6.8%), 
Canada (4.5%), Europe (4.1%) and the United States (1%) 
(Moses et al., 2015). Despite increasing investments in 
medical research by the Chinese government, China con-
tributes only 1.8% of global funding for medical research, 
much less than United States (44.2%), Europe (33.4%), and 
Japan (14.3%).  
The National Natural Science Foundation of China 
(NSFC), one of the major funding agencies that support 
academic research, established the Department of Health 
Science in 2009. NSFC awarded 1.1 billion RMB (US 
$ 0.18 billion) in medical research in 2009 and increased its 
funding to 4.4 billion RMB (US $ 0.71 billion) in 2013. 
Individual institutions such as universities and hospitals 
alike followed suit and established their own funds. During 
the period 20002013, the number of NSFC funded projects 
in medical sciences is much less lower than that of other 
departments. However, in the recent years the field of on-
cology lists at the top of all 86 research areas in terms of 
both the number of projects and funds. Oncology is paid 
more and more attention because cancer is one of the most 
deadly diseases, and the risk of cancer is increasing as well 
(Wu, 2015). 
During the period 19962011, the US S&T workforce 
increased by 2.7% annually to reach 1.25 million workers. 
Over the same period, China’s workforce increased 6% an-
nually to reach 1.31 million workers, making it the largest 
national S&T workforce in the world. Reliable information 
about the proportion of medical researchers could not, 
however, be obtained. But with regard to the talented scien-
tists, according to our investigation, the life sciences and 
medical sciences account for 25% of all the “Thousand 
Talents Program” between 2008 and 2015. There are 485 
“Changjiang Scholars” in medical sciences between 1999 
and 2015, accounting for 15% annually, and 151 scientists 
were awarded the National Science Fund for Distinguished 
Young Scholars in medical sciences, accounting for 13% 
annually. The two percentages are steadily increasing.  
Although China led the world in the overall size of S&T 
workforce, it had only 1.9 S&T workers per 100,000 
full-time equivalent employment population, the lowest 
among the countries for comparison, including United 
States (8.1), United Kingdom, Germany, Canada, France, 
Japan, South Korea, Russia and Spain. The investment in 
capital terms and in labor terms differ widely across coun-
tries and regions. The US contributes 44.2% of global med-
ical research funding but comprises only 21.2% of the glob-
al S&T workforce. Conversely, China contributes only 
1.8% of global funding for medical research but comprises 
22.3% of the global S&T workforce. 
PUBLICATIONS AND CITATIONS: 
INTERNATIONAL COMPARISON 
China’s capability in biomedical knowledge creation is 
growing rapidly. Figure 1 shows that during 20062010, the 
number of China’s biomedical papers (only article and re-
view included) in the Science Citation Index (SCI) ranked 
eighth in the world following US, UK, Germany, Japan, 
Italy, Canada, and France. But during 20112015, China 
ranked second in the world in the number of international 
biomedical publications. Moreover, China’s status as the 
fourth largest country contributor, which ranked behind US, 
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UK and Germany, to the Nature Index demonstrates its 
strength and progress in high-quality life sciences research.  
China quadrupled the global share from 2.4% (2006) to 
10.8% (2015) for biomedical articles. Over the same period, 
the global share consistently declined for US, UK, Germa-
ny, and Japan, and remained steady for Canada, Italy, and 
France.   
While the total number of biomedical papers for China 
ranked second behind the US between 2011 and 2015, the 
volume is only less than 1/3 of that of the US. The Category 
Normalized Citation Impact (CNCI) divides each publica-
tion’s citation count by the average citation count of all 
publications in that subfield and document type in that same 
year, and thus can be used for comparison. Table 1 illus-
trates that the average impact of China’s medical research 
publications lagged behind the world average level, and was 
also below the western nations. Among all publications, 
only a small share receives more than a handful of citations. 
Publications that are in the top 1% of total global citations 
can be considered to have the highest impact, once properly 
adjusted for subfield and year. Similar to the CNCI, country 
and region citation rates for highly cited publications need 
to be normalized for the share of total publications pro-
duced. Citations are calculated by percentile rankings, 
showing what share of publications are in the top 1% of the 
most highly cited literature. A country with a 2% share of 
the top 1% has twice as many highly cited articles as would 
otherwise be expected, based on its number of publications. 
During 20062015, the US medical publications have a 
2.01 and 1.92 share of the top 1%, meaning that these pub-
lications were almost twice as likely to be among the top 
1% as would be expected. Such pattern of citations also 
exists in UK, Germany, Canada, Italy, and France. Alt-
hough China and Japan have roughly the same average cita-
tion impact, the share of publications that are in the top 1% 
of the world’s citations, and the share of publications col-
laborated with industry relative to all the country’s publica-




Figure 1  (Color online) The number of China’s biomedical papers: international comparison during 20062015. 
Table 1  The citations of China’s biomedical papers: international comparison during 20062015 
Country 
Web of Science Documents Category Normalized Citation Impact % Documents in Top 1% % Industry Collaborations 
20062010 20112015 20062010 20112015 20062010 20112015 20062010 20112015 
US 667,958 768,079 1.38 1.38 2.01 1.92 3.08 2.80 
UK 168,820 196,632 1.37 1.54 2.03 2.44 4 4 
Germany 145,780 165,261 1.22 1.42 1.73 2.12 4.07 4.69 
Canada 95,010 116,904 1.41 1.5 2.09 2.24 2.92 2.72 
Italy 95,761 118,798 1.26 1.4 1.72 1.93 2.46 2.54 
France 91,312 100,740 1.23 1.51 1.94 2.40 4.12 4.57 
Japan 123,662 131,445 0.89 0.94 0.77 0.80 1.73 1.98 
the mainland of 
China 
75,027 202,983 0.93 0.91 0.66 0.57 0.81 0.74 
 
 Tang, X., et al.   Sci China Life Sci   October (2016) Vol.59 No.10 1077 
HIGH-QUALITY RESEARCH PUBLICATIONS 
The top 33 life sciences journals and the top 18 clinical re-
search journals are defined by Nature Index and Bouillon et 
al. (2015), respectively. The journals included in the Nature 
Index are selected by a panel of active scientists, inde-
pendently of Nature Publishing Group. The selection pro-
cess reflects researchers’ perceptions of journal quality, 
rather than using quantitative measures such as Impact Fac-
tor. Within the 33 high-quality life science journals includ-
ed, for multi-disciplinary journals, such as Science, Nature, 
Proceedings of the National Academy of Sciences of the 
United States of America (PNAS), and Nature Communica-
tions, only articles classified in life science areas are in-
cluded, i.e. the institution name has such terms as “med”, 
“hlth”, “hosp”, “life” and “bio” etc. 
The first and corresponding author(s) are the most im-
portant authors of a paper. We argued that on one hand, the 
first author is credited with having done most of the re-
search work, and on the other hand, the corresponding au-
thor may also has been considered to be primarily responsi-
ble for the writing of the paper, though not always (Du and 
Tang, 2013). In Table 2, the publications in which China’s 
authors act as the first author and/or the corresponding au-
thor increased significantly from the period 20062010 to 
the period 20112015.  
The majority of China’s life sciences publications belong 
to biological chemistry and molecular biology. Today, dis-
coveries and innovations in biological sciences and bio- 
technology continue to revolutionize medical research, re-
sulting in some advances that could not have been imagined 
even a decade ago. Progress in molecular biology, genomic  
sciences, cellular and tissue engineering, regenerative medi-
cine, proteomic technologies, bioengineering, bio-imaging, 
and computational methods are among the many advances 
that have served to accelerate the tempo of biomedical re-
search, to create unprecedented opportunities for advancing 
medical science, and to hold promise for improving clinical 
care and health outcomes. These sciences are the basis for 
the revolutions in personalized medicine (Fontanarosa and 
Bauchner, 2015). The majority of China’s clinical research 
publications relate to cancer, endocrinology & metabolism, 
blood, diabetes, gastroenterology, circulation, and leukemia. 
TRIADIC PATENT FAMILIES 
Using counts from a national patent office as an indicator of 
inventive activity may not differentiate between inventions 
of minor and substantial economic potential. Triadic patent 
families are a set of patents filed at three of these major pa-
tent offices: the European Patent Office (EPO), the Japan 
Patent Office (JPO) and the United States Patent and 
Trademark Office (USPTO) (OECD, 2016). These triadic 
patents serve as an indicator of higher-value inventions, and 
the number of triadic patents is strongly correlated with 
industrial R&D expenditures. Triadic patent family counts 
are fractionally attributed to the countries of residence of 




Figure 2  (Color online) US, EU, Japan and China’s triadic patent families in the fields of biotechnology, medical technology and pharmaceuticals. Source: 
OECD Statistic 2016 http://stats.oecd.org/Index.aspx?DatasetCode=PATS_IPC. 
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According to OECD.Stat (http://stats.oecd.org/Index. 
aspx?DatasetCode=PATS_IPC) updated on 12 May 2016, 
the total number of China’s triadic patent families in the 
fields of biotechnology, medical technology and pharma-
ceuticals is ranked below the developed countries, with only 
a global share of 0.8%, 0.4%, and 1.5%, respectively (Table 
3). Over the same period, the US’ global share in these three 
fields are more than 40%, whereas Japan’s global share are 
15%, 18%, and 10% in these three fields, respectively. 
It should be noted that the number of China’s pharma-
ceutical triadic patent families is rapidly increasing from 
1999 to 2011, compared with the steadily declining trend  
of the US, EU and the sharply declining trend of Japan 
(Figure 2).  
CHINA’S PATENTS GRANTED BY THE 
UNITED STATES AND EUROPEAN UNION 
The USPTO and EPO patent database were used with the 
purpose of facilitating comparison and removing any inter-
nal bias in the grants made by inventors. The patents ana-
lyzed in this research come from IPC class A61K and/or 
A61P for the period 1976–2015. Class A61K corresponds to 
“preparations for medical, dental, or toilet purposes”, while 
class A61P belongs to “specific therapeutic activity of 
chemical compounds or medicinal preparations”. In the 
above two classes, there are totally 2,006 and 832 patents 
granted by the USPTO and the EPO, respectively to Chi-
nese inventors and/or assignees during the period 
1988-2015. China’s biomedical patents granted by the US 
and the EU are also increasing (Figure 3). 
China’s first medical patent granted by USPTO appeared 
in 1988, about “pharmacologically active bicyclic lactams” 
(US4757064), with Bayer Aktiengesellschaft (DE) and 
Chinese Academy of Medical Sciences (CN) as the assign-
ees. China’s first independently invented patent was granted 
by USPTO in 1989, about “topical application of glyci-
phosphoramide”, with Chinese Academy of Medical Sci-
ences (CN) as the assignee. Since the Project “Creation & 
Development of Innovative Drugs” initiated in 2008, the 
count of patents sharply increased. The Chinese government 
launched the project “Key Drug Innovation” in 2007, which 
provides R&D funding for the pharmaceutical sector. The 
project provided $ 1 billion during 2011–2015 and is ex-
pected to add investments to approximately $ 4.3 billion by 
2020 (Ding et al., 2011). As an important national project, 
Key Drug Innovation aims to develop a series of innovative 
drugs for treating ten major diseases. Since the project’s 
inception, China’s drug innovation has been greatly im-
pelled. 
The most popular technology area for both USPTO   
and EPO patents granted to Chinese inventors/assignees is 
“medicinal preparations containing organic active ingredi-
ents” (A61K-031/00). Nevertheless, the technology area 
patterns of China’s patents differ between USPTO and  
Table 2  Top Journals’ publications in which China’s authors act as the 
first authors and/or the corresponding authorsa) 




Journal of Biological Chemistry 461 1,029 
Proceedings of the National Academy of Sciences of the  
United States of America 
149 414 
Nature Communications 1 335 
Journal of Neuroscience 75 193 
Nature 26 90 
Nature Genetics 24 94 
Science 29 61 
Molecular Cell 18 50 
Proceedings of the Royal Society B-Biological Sciences 29 39 
Journal of Clinical Investigation 17 45 
Cell 14 47 
Embo Journal 25 36 
American Journal of Human Genetics 25 29 
Current Biology 13 38 
Cell Stem Cell 8 42 
Developmental Cell 9 40 
Genome Research 22 26 
Genes & Development 11 36 
Ecology 11 31 
Journal of Cell Biology 13 29 
Nature Cell Biology 15 27 
Neuron 14 24 
Nature Immunology 14 22 
Nature Neuroscience 14 18 
Nature Structural & Molecular Biology 2 29 
Nature Medicine 7 23 
Plos Biology 1 28 
Cell Metabolism 8 20 
Nature Biotechnology 6 21 
Immunity 5 19 
Ecology Letters 4 18 
Nature Chemical Biology 2 14 
Nature Methods 0 8 
Cancer Research 146 172 
Journal of Clinical Endocrinology & Metabo 
lism 
40 151 
Blood 72 103 
Diabetes 31 95 
Gastroenterology 38 70 
Circulation 24 35 
Leukemia 31 24 
Lancet 18 35 
Journal of the American College of Cardiology 21 31 
Clinical Journal of the American Society of Nephrology 11 31 
European Heart Journal 17 20 
American Journal of Respiratory and Critical Care
Medicine 
13 21 
Nature Medicine 7 23 
New England Journal of Medicine 14 16 
Annals of the Rheumatic Diseases 7 19 
JAMA-Journal of the American Medical Associ ation 8 8 
Annals of Internal Medicine 8 5 
Archives of Internal Medicine 8 0 
a) Only articles and review are included. Nature Communications was 
created in 2010. 
 Tang, X., et al.   Sci China Life Sci   October (2016) Vol.59 No.10 1079 
Table 3  Triadic patent families during 1999–2011 in the fields of biotechnology, medical technology and pharmaceuticalsa) 
Inventor’s country of residence 
Biotechnology Medical technology Pharmaceuticals 
Rank % Rank % Rank % 
United States 1 41.1 1 43.4 1 42.7 
European Union (28 countries) 2 30.7 2 26.8 2 33.7 
Japan 3 14.9 3 18.7 4 9.6 
Germany 4 9.0 4 9.4 3 9.6 
United Kingdom 5 5.4 5 4.8 5 7.0 
France 6 5.2 6 3.3 6 5.5 
Canada 7 2.4 14 1.2 9 2.4 
Korea 8 2.2 11 1.5 11 1.7 
Netherlands 9 2.1 8 2.2 15 1.3 
Denmark 10 1.9 15 1.1 12 1.5 
Switzerland 11 1.9 7 2.6 7 2.6 
Australia 12 1.8 12 1.5 14 1.3 
Sweden 13 1.6 10 2.1 10 1.8 
Italy 14 1.5 13 1.3 8 2.6 
Belgium 15 1.2 17 0.5 18 1.2 
Israel 16 1.1 9 2.2 17 1.2 
Austria 17 0.9 16 0.6 20 0.7 
Spain 18 0.8 19 0.4 16 1.2 
China (People’s Republic of) 19 0.8 18 0.4 13 1.5 
Finland 20 0.5 20 0.4 22 0.3 
India 21 0.5 24 0.2 19 1.1 
Singapore 22 0.4 23 0.2 28 0.2 
Norway 23 0.4 22 0.3 21 0.4 
New Zealand 24 0.3 25 0.2 25 0.2 
Chinese Taipei 25 0.3 26 0.2 23 0.3 
a) Source: OECD Statistic 2016. http://stats.oecd.org/Index.aspx?DatasetCode=PATS_IPC 
 
Figure 3  (Color online) Medical patents granted by USPTO and EPO to 
Chinese in ventors and/or assignees during the period 1988–2015 
EPO. China’s patents granted by USPTO are relative to 
basic research, for example, the other top 10 technology 
areas are “biocides, pest repellants or attractants, or plant 
growth regulators containing heterocyclic compounds”, 
“heterocyclic compounds containing two or more hetero 
rings, having nitrogen atoms as the only ring hetero atoms, 
at least one ring being a six-membered ring with only one 
nitrogen atom”, “medicinal preparations of undetermined  
 
Figure 4  Top 10 technology areas of USPTO and EPO for patents 
granted to Chinese inventors/assignees 
constitution containing material from algae, lichens, fungi 
or plants, or derivatives thereof, e.g. traditional herbal med-
icines”, “medicinal preparations containing antigens or an-
tibodies”, “medicinal preparations characterized by special 
physical form” and “medicinal preparations containing pep-
tides”. While China’s patents granted by EPO are relative to 
drug development, for example, the other top 10 technology 
areas are “drugs for disorders of the cardiovascular system”, 
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“drugs for disorders of the nervous system”, “drugs for dis-
orders of the metabolism”, “antiinfectives, i.e. antibiotics, 
antiseptics, chemotherapeutics” and “antineoplastic agents”. 
KEY PATENTS REFERRING TO USFDA 
APPROVED DRUGS INVENTED BY CHINA 
The United States is the world’s largest pharmaceutical 
market, comprising roughly 40% of the world’s pharmaceu-
tical revenues and, thus, always acts as benchmark in the 
scientific drug regulatory system. Moreover, since its rela-
tively rigorous regulatory system of drugs and Intellectual 
Property (IP), the US is always chosen as the first target 
market by the majority of worldwide pharmaceutical firms, 
making it a good environment to examine the worldwide 
distribution of pharmaceutical innovation. An additional 
benefit to focusing on drugs marketed in the US stems from 
its relatively simple regulatory structure. Approval deci-
sions in the United States are made by a single body—the 
Food and Drug Administration (FDA)—which requires 
drug companies to list the patents that protect their drugs in 
the FDA Orange Book. This linkage between drugs and 
patents facilitates assessment of the location of innovation, 
because the US Patent and Trademark Office (USPTO) re-
quires that a patent lists all the inventors.  
Recent work seems to confirm the dominant status of the 
US in the global pharmaceutical landscape by investigating 
the geographical distribution of pharmaceutical innovation, 
as captured by patent applications referring to new drugs. 
Friedman (2010) explored the geographical location of 
pharmaceutical innovation during the time period 2000– 
2009 at the country level, separately examining the fre-
quency of drug patent inventors of specific countries 
(Friedman, 2010). Hu et al. (2013) took the key patents 
covering all new drugs approved by the Food and Drug 
Administration between 1996 and 2010 as sample to inves-
tigate the role of the US in global pharmaceutical innovation.  
In this article, we follow Friedman and Hu et al. in using 
US patents to track the global distribution of R&D in the 
pharmaceutical sector. Our sample is composed of key pa-
tents covering all new drugs approved by the Food and 
Drug Administration (FDA) from prior to January 1, 1982 
to 2015. Key patents of a new drug are identified as relevant 
patents listed in the annual Orange Book in the same year to 
approve this drug, in order to avoid noise from insignificant 
and supplemental technology improvement at the late stage 
of pharmaceutical lifecycle. In this sense, the innovation in 
this study is exactly confined to be innovation outputs 
which are measured by patents related to marketed drugs, 
rather than innovation inputs or common innovation out-
puts, e.g. ‘‘sleeping’’ patents without contributions to re-
al-world pharmaceutical products.  
Totally, our dataset comprises 3,299 patents of drugs 
(RX and OTC included, DISCN excluded). The first inven-
tors’ country code of FDA approved drug patents are re-
trieved from the database of the United States Patent and 
Trademark Office (USPTO). Figure 5 shows the United 
States has the largest proportion (61.7%) of drug patent in-
ventors around the world. The European Union countries 
accounts for 28.7% and Japan 5%. The performance of Is-
rael is better than the mainland of China, which only has six 
patents referring to substances, products and method-of-use 
of marketed drugs.  
In the above six patents, there are four patents in which 
China also is the assignee, while the other two patents with 
China as the inventor’s country, but not the assignee’s 
country (the assignee is Ferring International). There are 
only three Chinese invented patents referring to substances, 
products and method-of-use of two FDA marketed drugs. 
Veregen (sinecatechins) 
In 2006, FDA approved the first botanical drug product for 
Veregen (sinecatechins), for treatment of external genital 
and perianal warts, showing that new therapies derived from 
 
 
Figure 5  Country or region of the first inventors of key patents referring to FDA approved drugs. 
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natural complex mixtures can be developed to meet modern 
FDA standards of quality, safety, and efficacy. Sinecate- 
chins is a water extract of green tea leaves from Camellia 
sinensis. It is a mixture of catechins and other green tea 
components. The key original patents of Veregen are in-
vented by Shujun Cheng, who worked at Cancer Institute 
(Hospital) of Chinese Academy of Medical Sciences and 
discovered the inhibition of antioxidant catechins isolated 
from Chinese green tea on mutagenicity and carcinogenicity 
in the 1980s. Since 1990, Mitsui Norin Company, Ltd., To-
kyo, joined the clinical research. The patent “composition for 
treating Condyloma acuminata” and “method for treating 
hyperplasia” were granted by the USPTO in 1998 and 1999. 
The patents were licensed to Medigene company, Germany 
for Phase 2 and Phase 3 clinical trials. The Veregen drug 
was finally approved by FDA on October, 31, 2006.  
Coartem (Artemether/Lumefantrine) 
This is a combination of the two medications artemether 
and lumefantrine. Artemether is one derivative of artemis-
inin (originally known as qinghaosu), discovered by Youy-
ou Tu and her research group in 1972. In 1981 Qiqing Zhou 
at the Institute of Microbiology and Epidemiology of the 
Academy of Military Medical Sciences start to specifically 
work on artemether. Zhou showed that artemether combined 
with another antimalarial lumefantrine was the most potent 
of all antimalarial drugs. He worked alone for four years, 
and was joined by Dianxi Ning and his team in 1985. They 
found that in clinical trials the combined tablet (arteme-
ther/lumefantrine) had a very high cure rate of severe ma-
laria, more than 95%, including in areas where multi-drug 
resistance is experienced. They applied for a US patent in 
1997. Novartis then noticed the new drug and made a deal 
for mass production. In 1999 Novartis obtained the interna-
tional licensing rights and gave the brand name Coartem. It 
was approved by the USFDA in 2009. It became the first 
artemisinin-based combination therapy. For this invention 
he and his team were awarded the European Inventor 
Award of 2009. 
CONCLUSION 
With a substantial increase in research investment, especially 
in the field of biomedical sciences, China has risen as a major 
contributor to the global scientific and technological devel-
opment. The intensity of R&D expenditure in pharmaceutical 
industry has been ranked top three in more than 30 domestic 
manufacturing industries and the R&D expenditure in phar-
maceutical industry reached 39.03 billion RMB in 2014. Our 
investigation indicates that scientific outputs were closely 
related with the increasing in scientific funds and large S&T 
workforce. Meanwhile, the study also indicates that Chinese 
scholars need to improve their academic impact and develop 
high-valued patents. In order to improve the country’s capa-
bility in innovation research and scientific achievements, the 
following suggestions are proposed. 
Funding more basic science. 
While China spent 2.1 percent of its GDP on R&D in 2014, 
in line with other developed countries such as the US and 
the UK, it spent only a fraction of that on basic research. 
Given that many important advances in applied research 
originate with advances in fundamental understanding, 
boosting basic research funding would be a prescient 
long-term strategy for fostering innovation.  
Addressing Gaps in S&T Workforce. 
While China has the largest base of PhD students and the 
largest S&T workforce in the world, there are two major 
gaps in its workforce — a lack of lab technicians and 
post-doctoral fellows, according to Turning Point: Chinese 
Science in Transition by Nature Publishing Group in 2015 
(http://www.nature.com/ press_releases/turning_point.pdf). 
This is in contrast with the West, which sees a surplus of 
postdocs, many of whom come from China. Postdocs and 
technicians are valuable members of the Chinese research 
environment. Experienced postdocs can make PI’s time 
more scalable and can also play a key role in mentoring 
junior students and staff. Competent technicians play an 
increasingly important role as more research requires 
equipment and technologies needing significant technical 
skills to use effectively. Addressing these shortages will be 
critical for Chinese science to continue competing on a 
global stage, and will probably require a promotion of the 
value institutes place on these positions. Greater compensa-
tion for contract-based researchers, less emphasis on hiring 
researchers with overseas experience and reforming strict 
hiring rules are some clear measures that would help ad-
dress these shortfalls. 
Striking a balance between basic research and clinical 
research 
The US National Institutes of Health (NIH) defines clinical 
research as research that directly involves human subjects or 
human tissues. It can be patient oriented research, epidemio-
logical and behavioral studies, or outcomes research and 
health services research. NIH allocates around 55% to basic 
biomedical research and 45% to applied research (Moses et 
al., 2015). Despite increasing investments in medical research 
by the Chinese government, funding for clinical research was 
only a quarter of that for basic biomedical research (US 
$250 million vs $1 billion in 2013) (Jiang et al., 2015).  
China accounts for 20% of the world’s population. The 
patient volume is enormous. Improved patient care and 
population health is a huge responsibility and should, 
therefore, be a high national priority for research. In recog- 
nition of its importance, the Ministry of Science and Tech- 
nology of China (MOST) and National Health and Family 
Planning Commission established 32 national clinical re- 
search centers (CRCs) focusing on 11 major diseases be- 
tween 2013 and 2016. Although highly commendable, a 
small number of national CRCs might be insufficient to 
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Table 4  Key patents referring to FDA approved drugs invented by China 
Patent Drug Approved Year 
Trade_Name/ 
Ingredient 
Applicant Inventors Assignees 
Method for treating hyperplasia 
Patent Number: US5968973 
Grant year:1999 
2006 Veregen/Sinecatechins Medigene AG 
ShuJun Cheng [CN] 
Dechang Wang [CN] 
Yukihiko Hara [JP] 
Cancer Institute (Hospital), Chi-
nese Academy of Medical Scienc-
es, Beijing [CN] 
Mitsui Norin Company, Ltd., 
Tokyo [JP] 
Title: Composition for treating 
Condyloma acuminata 
Patent Number: US5795911 
Grant year:1998 
2006 Veregen/Sinecatechins Medigene AG 
Title: Antimalarial compositions 







Yiqing Zhou [CN] 
Dianxi Ning [CN] 
Shufen Wang [CN] 
Deben Ding [CN] 
Guofu Li [CN] 
Chengqi Shan [CN] 
Guangyu Liu [CN] 
Ciba-Geigy AG, Basel [CH] 
Institute of Microbiology and 
Epidemiology, Academy of Mili-
tary Medical Sciences, Beijing 
[CN] 
 
raise the level of clinical research nationwide. More efforts 
and investments are warranted at all levels. High-quality 
clinical studies need substantial investment in expertise, 
manpower, and infrastructure. We have huge patient re-
sources that can be used to answer many clinical questions. 
“Setting research priorities which are most likely to deliver 
improved health outcomes”—the first strategic aim of the 
UK Medical Research Council—is equally applicable in 
China (Zhang et al., 2015). With the right policy and suffi-
cient investment at all levels, China has the potential to be-
come a fertile field for clinical research. 
Enhancing drug discovery and drug development. 
Drug development is the process of bringing a new phar-
maceutical drug to the market once a lead compound has 
been identified through the process of drug discovery. It 
includes pre-clinical research on microorganisms and ani-
mals, clinical trials on humans, and may include the step of 
obtaining regulatory approval to market the drug. The na-
ture of a drug development project is characterized by mul-
ti-disciplinarity, large capital expenditure, and a long cycle 
of R&D. As a result, collaboration between pharmaceutical 
companies and universities or research institutes will help to 
reduce risk and improve the chances of success. For in-
stance, on March 15, 2016, Huya Bioscience announced 
that it had signed an exclusive license with China’s Fudan 
University for the ex-China rights to a series of novel im-
muno-oncology drug candidates discovered by Fudan re-
searchers. At the national level, China has shifted its focus 
to the establishment of translational medicine centers, which 
aims at breakthrough of bottlenecks between basic medical 
research, clinical research and drug development by trans-
lating laboratory findings into clinical applications. Five 
National Centers for Translational Medicine are under con-
struction now, which will greatly promote the development 
of medical level and drug development in China. 
There are several limitations in this study. First, the sam-
ple is limited to English journal articles. But in China a sub-
stantial number of Chinese authors published papers in 
Chinese. Excluding Chinese language publications means  
the results can be biased and cause uncertainty. Second, our 
investigation is a descriptive study and the results are tenta-
tive. Due to the lack of appropriate measurement models 
and reliable information about the proportion of medical 
researchers in China, it is hard to precisely estimate the re-
lationship between scientific output and investment in sci-
ence. For example, our investigation shows that past in-
vestments in science are related with current scientific out-
put, but it is uncertain whether R&D input is related with 
scientific output per researcher. We will address these limi-
tations in future studies. 
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